A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
Wet Macular Degeneration, Neovascular Age-related Macular Degeneration, Macular Degeneration
About this trial
This is an interventional treatment trial for Wet Macular Degeneration focused on measuring siRNA, oligonucleotide
Eligibility Criteria
Inclusion Criteria: Signed informed consent Active subfoveal or juxtafoveal choroidal neovascularization secondary to AMD Best Corrected Visual Acuity (BCVA) between 70-25 letters (ETDRS) at Screening Intraretinal or subretinal fluid Central Subfield Thickness > 300 µm Exclusion Criteria: Pregnant or breastfeeding females or those with a positive pregnancy test. Females of childbearing potential who will not use a medically acceptable contraceptive method Current, previous chronic or recurrent condition according to the investigator's judgement. Concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications Concurrent disease in the study eye Previous treatment with systemic anti-Vascular Endothelial Growing Factor (Anti-VEGF) drugs or pro-VEGF treatments Concurrent disease in the study eye, other than AMD
Sites / Locations
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
- SYL1801 Investigative SiteRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
SYL1801 ophthalmic solution Low Dose once daily
SYL1801 ophthalmic solution Middle Dose once daily
SYL1801 ophthalmic solution High Dose once daily
42 treatment days
42 treatment days
42 treatment days